COLUMBIA, Md., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) Fall Conference. A total of 10 studies (6 clinical and 4 scientific studies) will be presented.
The clinical studies highlight benefits of Osiris' placenta-based products, Grafix® and Stravix®, for use in covering a variety of wound types in both the outpatient and operative settings. The scientific studies describe the cell phenotype and anti-microbial properties of placental tissues, as well as Osiris' novel lyopreservation technology allowing ambient storage of viable tissues. Key presentations and events are highlighted below.
Dr. Eric Johnson, MD, will present a lecture entitled "A Comparative Outcomes Analysis Evaluating Clinical Effectiveness in Two Different Human Placental Membrane Products for Wound Management" on Friday, October 20, at 7:30am (Milano VII-VIII Room, onsite registration available). This is the first study comparing outcomes of two human
placental products used for management of acute and chronic wounds. As a comparative effectiveness study, the patient cohort reflects the variety of wounds and comorbidities seen daily in wound care centers and the outcomes of placental product use in this population.
Osiris is supporting a CME lecture entitled "Clinical and Scientific Advances in the Use of Placental Membranes" on Saturday, October 21 at 11:20am (Forum 17-19). The lecture will be presented by Dr. Lawrence A. Lavery, DPM, MPH, and will overview the science of placental membranes and their use in chronic and complex wounds. The lecture will also discuss when and how to utilize placental membranes as an adjunct to good wound care.
A study by Osiris scientists was selected as one of eight abstracts for oral presentation during the conference. The study entitled
"Ambient Temperature Viable Amnion Processed via Novel Lyopreservation Method Retains Properties of Fresh Tissue" will be presented on Saturday, October 21 at 11:20am (Oral Abstract 25.4, Forum 1-4). This podium presentation describes the results of in vitro and in vivo evaluation of viable lyopreserved amniotic membrane (VLAM) and viable cryopreserved amniotic membrane (VCAM). VLAM is processed using a novel lyopreservation technology that allows for ambient storage of living tissues. Data demonstrates that both VCAM and VLAM retain the structure, cell viability, and functional properties of fresh amniotic membrane. However, VLAM is stored at ambient temperatures making VLAM more accessible for widespread use. Results will also be presented at the poster session (Poster LB-008).
In addition to the oral presentation,
Osiris' scientific poster was selected for the SAWC Research Poster Critique Recognition ("Utility of a New Chronic Wound Model in Diabetic Mice for Evaluation of Wound Care Products," Abstract LB-009), and three clinical abstracts were selected for publication in WOUNDS as Rapid Communication video reports. Video reports can be viewed online at: http://www.woundsresearch.com/.
The complete list of scientific and clinical abstracts includes:
Scientific Oral Presentation:
- "Ambient Temperature Viable Amnion Processed via Novel Lyopreservation Method Retains
Properties of Fresh Tissue" (Oral Abstract 25.4, Sat, Oct 21, 11:20am; Poster Abstract LB-008)
SAWC Research Poster Critique Recognition:
- "Utility of a New Chronic Wound Model in Diabetic Mice for Evaluation of Wound Care Products" (Abstract LB-009)
Clinical Poster Presentations:
- "Sickle Cell Disease: Case Report of a Patient With Foot Ulceration Treated With Viable Cryopreserved Placental Membrane" (Abstract CS-018)
- "Utilization of a Viable Human Amnion Membrane Allograft in Elderly Patients with Chronic Lower Extremity Wounds of Various Etiologies" (Abstract CS-061)
- "Successful Use of Viable Cryopreserved Placental Membrane with Hyperbaric Oxygen Therapy on Non-Healing Diabetic Amputation Wounds" (Abstract
Scientific Poster Presentations:
- "Phenotypic Characteristics of Cells Isolated from Human Amniotic and Chorionic Membranes" (Abstract LB-026)
- "Inhibition of Bacterial Growth by Human Cryopreserved Viable Amniotic Membrane Mediated by Soluble Antimicrobial Peptides" (Abstract LB-030)
Clinical Posters Selected for Rapid Communication publications in WOUNDS:
- "Surgical Application of Viable Cryopreserved Placental Membrane for the Treatment of Chronic Wounds in 11 High-Risk Patients" (Abstract CS-017)
- "One-Time Application of Viable Cryopreserved Umbilical Tissue for Treatment of Surgical Amputation Wounds in High-Risk Patients: A 10-Case Series" (Abstract CS-049)
Major Amputation in a Patient With High-Risk Peripheral Arterial Disease Using Viable Cryopreserved Placental Membrane: A Case Report" (Abstract CS-050)
Osiris Therapeutics will also be exhibiting at the Symposium on Advanced Wound Care Fall Meeting at booth 207. The event runs from October 20 through October 22, 2017 at Caesar's Palace in Las Vegas, Nevada.
About Osiris Therapeutics
Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix®, BIO4® (available exclusively through Stryker), and Cartiform® (available exclusively through Arthrex). Osiris, Grafix, Stravix and Cartiform are
trademarks of Osiris Therapeutics, Inc., and BIO4 is a trademark of Howmedica Osteonics Corp. Osiris makes no claims concerning functional activities of Grafix or Stravix. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. More information can be found on the Company's website, www.Osiris.com. (OSIR-G)
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding the potential uses of Prestige™ Lyotechnology and the publication of Osiris's profile in Nature (www.nature.com). Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from
those expected or implied by the forward-looking statements. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
For additional information, please contact:
Osiris Therapeutics, Inc.
Source: Osiris Therapeutics, Inc.
News Provided by Acquire Media